Lundbeck has licensed the drug from Biotie Therapies and performed clinical trials with nalmefene for treatment of alcohol-dependence.
Lundbeck |
Melitracen (Adaptol, Dixeran, Melixeran, Thymeol, Trausabun) is a tricyclic antidepressant (TCA) marketed in Europe and Japan by Lundbeck and Takeda, respectively, for the treatment of depression and anxiety.